
    
      Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which
      could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent
      human genome. So investigators design Radiotherapy plus Endostar to treat Pediatric
      Neuroblastoma to research the RR and safety. Investigators believe this treatment regimen may
      be a new approach to the pediatric neuroblastoma patients.
    
  